##chargement des packages----
library(questionr)
library(tidyverse)
## ── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
## ✔ dplyr 1.1.1 ✔ readr 2.1.4
## ✔ forcats 1.0.0 ✔ stringr 1.5.0
## ✔ ggplot2 3.4.2 ✔ tibble 3.2.1
## ✔ lubridate 1.9.2 ✔ tidyr 1.3.0
## ✔ purrr 1.0.1
## ── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
## ✖ dplyr::filter() masks stats::filter()
## ✖ dplyr::lag() masks stats::lag()
## ℹ Use the conflicted package (<http://conflicted.r-lib.org/>) to force all conflicts to become errors
library(tableone)
library(labelled)
library(gtsummary)
library(GGally)
## Registered S3 method overwritten by 'GGally':
## method from
## +.gg ggplot2
library(readxl)
library(effects)
## Le chargement a nécessité le package : carData
## lattice theme set by effectsTheme()
## See ?effectsTheme for details.
library(survival)
library(survminer)
## Le chargement a nécessité le package : ggpubr
##
## Attachement du package : 'survminer'
##
## L'objet suivant est masqué depuis 'package:survival':
##
## myeloma
library(ggplot2)
library(dplyr)
library(knitr)
library(cowplot)
##
## Attachement du package : 'cowplot'
##
## L'objet suivant est masqué depuis 'package:ggpubr':
##
## get_legend
##
## L'objet suivant est masqué depuis 'package:lubridate':
##
## stamp
##chargement des données
recap_survies_v20260424 <- read_excel("C:/datar/recap_survies_v20260424.xlsx")
## New names:
## • `nom jeune fille` -> `nom jeune fille...19`
## • `date_os` -> `date_os...55`
## • `nom jeune fille` -> `nom jeune fille...59`
## • `date_os` -> `date_os...81`
## • `` -> `...99`
##recodage des variables et bases de données le cas échéant----
cbnpc<-filter(recap_survies_v20260424, c(eligible_v2=="oui" ))
##motif exclusions##
exclus<-filter(recap_survies_v20260424, c(eligible_v2=="non" ))
tbl_summary(
exclus, include = c("motif_ineligibilite_2"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 3,424 |
| motif_ineligibilite_2 |
|
| alk |
29 (0.8%) |
| chit |
33 (1.0%) |
| cpc |
557 (16.3%) |
| egfr |
99 (2.9%) |
| essais_clinique |
421 (12.3%) |
| her2 |
20 (0.6%) |
| hors_onco |
19 (0.6%) |
| hors_oncothoracique |
78 (2.3%) |
| maladie_M0 |
681 (19.9%) |
| mesotheliome |
184 (5.4%) |
| pas de donnee |
25 (0.7%) |
| patient_hors_chu |
515 (15.0%) |
| pediatrie |
1 (0.0%) |
| raf_mek |
9 (0.3%) |
| suite_traitement_1ere_ligne_ailleurs_ou_avant_2010 |
748 (21.8%) |
| traitement_non_administré |
4 (0.1%) |
| vegfr |
1 (0.0%) |
##création de variables à plusieurs catégorie selon valeurs variable continue
cbnpc$old70<-ifelse(cbnpc$age_initiation>70, 1, 0)
cbnpc$old65<-ifelse(cbnpc$age_initiation>65, 1, 0)
cbnpc$maigres<-ifelse(cbnpc$imc<18.5, 1, 0)
cbnpc$surpoids<-ifelse(cbnpc$imc>25, 1, 0)
cbnpc$obeses<-ifelse(cbnpc$imc>30, 1, 0)
cbnpc$bsa_cap<-ifelse(cbnpc$bsa>2, 1, 0)
cbnpc$young57<-ifelse(cbnpc$age_initiation<57, 1, 0)
cbnpc$ir60<-ifelse(cbnpc$dfg_ml_min<60, 1, 0)
cbnpc$ir30<-ifelse(cbnpc$dfg_ml_min<30, 1, 0)
cbnpc$ere <- cut(cbnpc$annee, c(2010, 2015, 2018, 2024))
cbnpc$initiation_period<-factor(cbnpc$periode, levels=c(1, 2, 3, 4),
labels=c("immunotherapy not available",
"immunotherapy avilable as 2nd line",
"immunotherapy available as 1st line monotherapy",
"chemo_immunotherapy available as 1st line"))
##renommer des variables pour présentation dans les tableaux de résultats
library(labelled)
var_label(cbnpc$old65) <- "Patients older than 65 years"
var_label(cbnpc$old70) <- "Patients older than 70 years"
var_label(cbnpc$young57) <- "Patients younger than 57 years"
var_label(cbnpc$maigres) <- "Patients with BMI <18.5"
var_label(cbnpc$surpoids) <- "Patients with BMI >25"
var_label(cbnpc$obeses) <- "Patients with BMI >30"
var_label(cbnpc$bsa_cap) <- "Patients with BSA >2"
var_label(cbnpc$initiation_period) <- "period according to immunotherapy availability"
var_label(cbnpc$ir30) <- "Patients with GFR<30 ml/min"
var_label(cbnpc$ir60) <- "Patients with GFR<60 ml/min"
var_label(cbnpc$immuno) <- "Patients treated with immunotherapy at any line"
var_label(cbnpc$avastin) <- "Patients treated with bevacizumab at any line"
var_label(cbnpc$histologie) <- "Histologic category"
var_label(cbnpc$protocole_generique_initiation) <- "First line treatment"
var_label(cbnpc$age_initiation) <- "Age at the start of first line"
var_label(cbnpc$tt_initial) <- "First line treatment category"
var_label(cbnpc$imc) <- "Body Mass Index at the start of first line"
var_label(cbnpc$bsa) <- "Body Surface Area"
var_label(cbnpc$poids) <- "Body weight at the start of first line"
var_label(cbnpc$dfg_ml_min) <- "Glomerular filtration Rate at the start of first line"
var_label(cbnpc$sexe.cat) <- "Sex"
##tableau descriptif population globales ----
tbl_summary(
cbnpc, include = c("age_initiation", "old65", "old70","young57","sexe.cat","poids",
"imc","maigres","surpoids","obeses","bsa_cap","dfg_ml_min",
"tt_initial","histologie",
"imc","immuno", "avastin"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 2,130 |
| Age at the start of first line |
63 (57, 70) |
| Patients older than 65 years |
899 (42.2%) |
| Patients older than 70 years |
521 (24.5%) |
| Patients younger than 57 years |
557 (26.2%) |
| Sex |
|
| F |
759 (35.6%) |
| H |
1,371 (64.4%) |
| Body weight at the start of first line |
66 (56, 76) |
| Body Mass Index at the start of first line |
22.9 (20.0, 25.8) |
| Patients with BMI <18.5 |
284 (13.3%) |
| Patients with BMI >25 |
664 (31.2%) |
| Patients with BMI >30 |
173 (8.1%) |
| Patients with BSA >2 |
315 (14.8%) |
| Glomerular filtration Rate at the start of first line |
91 (76, 104) |
| Unknown |
27 |
| First line treatment category |
|
| chimio |
1,563 (73.4%) |
| chimio_immuno |
403 (18.9%) |
| immuno |
164 (7.7%) |
| Histologic category |
|
| epidermoide |
775 (36.4%) |
| non_epidermoide |
1,355 (63.6%) |
| Patients treated with immunotherapy at any line |
1,065 (50.0%) |
| Patients treated with bevacizumab at any line |
263 (12.3%) |
##détail traitements 1er ligne---
tbl_summary(
cbnpc, include = c("protocole_generique_initiation"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 2,130 |
| First line treatment |
|
| cemiplimab |
8 (0.4%) |
| pembrolizumab |
156 (7.3%) |
| platine_alimta |
756 (35.5%) |
| platine_alimta_avastin |
129 (6.1%) |
| platine_alimta_nivolumab |
6 (0.3%) |
| platine_alimta_pembro |
335 (15.7%) |
| platine_docetaxel |
56 (2.6%) |
| platine_gemcitabine |
67 (3.1%) |
| platine_gemcitabine_avastin |
6 (0.3%) |
| platine_gemcitabine_nivolumab |
1 (0.0%) |
| platine_taxol |
230 (10.8%) |
| platine_taxol_avastin |
8 (0.4%) |
| platine_taxol_nivolumab |
2 (0.1%) |
| platine_taxol_pembro |
59 (2.8%) |
| platine_vinorelbine |
311 (14.6%) |
##tableau descriptif population selon période d'initiation de tt----
tbl_summary(
cbnpc, include = c("age_initiation", "old65","old70","young57","sexe.cat","poids",
"imc","maigres","obeses","surpoids","bsa_cap","dfg_ml_min",
"tt_initial","histologie",
"imc","immuno", "avastin"),
by="initiation_period",
digits=all_categorical()~ c(0,1)
)%>%
add_p()
| Characteristic |
immunotherapy not available, N = 596 |
immunotherapy avilable as 2nd line, N = 384 |
immunotherapy available as 1st line monotherapy, N = 399 |
chemo_immunotherapy available as 1st line, N = 751 |
p-value |
| Age at the start of first line |
62 (55, 69) |
63 (56, 69) |
65 (58, 71) |
64 (58, 71) |
<0.001 |
| Patients older than 65 years |
220 (36.9%) |
145 (37.8%) |
189 (47.4%) |
345 (45.9%) |
<0.001 |
| Patients older than 70 years |
119 (20.0%) |
76 (19.8%) |
117 (29.3%) |
209 (27.8%) |
<0.001 |
| Patients younger than 57 years |
184 (30.9%) |
110 (28.6%) |
86 (21.6%) |
177 (23.6%) |
0.002 |
| Sex |
|
|
|
|
0.008 |
| F |
185 (31.0%) |
130 (33.9%) |
163 (40.9%) |
281 (37.4%) |
|
| H |
411 (69.0%) |
254 (66.1%) |
236 (59.1%) |
470 (62.6%) |
|
| Body weight at the start of first line |
66 (56, 76) |
66 (56, 76) |
66 (56, 77) |
65 (56, 76) |
0.9 |
| Body Mass Index at the start of first line |
22.9 (19.9, 25.6) |
22.7 (19.9, 25.8) |
23.2 (20.2, 26.4) |
22.8 (20.0, 25.6) |
0.4 |
| Patients with BMI <18.5 |
76 (12.8%) |
60 (15.6%) |
46 (11.5%) |
102 (13.6%) |
0.4 |
| Patients with BMI >30 |
50 (8.4%) |
36 (9.4%) |
27 (6.8%) |
60 (8.0%) |
0.6 |
| Patients with BMI >25 |
180 (30.2%) |
121 (31.5%) |
144 (36.1%) |
219 (29.2%) |
0.10 |
| Patients with BSA >2 |
89 (14.9%) |
60 (15.6%) |
61 (15.3%) |
105 (14.0%) |
0.9 |
| Glomerular filtration Rate at the start of first line |
90 (74, 102) |
92 (77, 104) |
90 (74, 103) |
93 (79, 106) |
0.007 |
| Unknown |
14 |
5 |
2 |
6 |
|
| First line treatment category |
|
|
|
|
<0.001 |
| chimio |
596 (100.0%) |
384 (100.0%) |
319 (79.9%) |
264 (35.2%) |
|
| chimio_immuno |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
403 (53.7%) |
|
| immuno |
0 (0.0%) |
0 (0.0%) |
80 (20.1%) |
84 (11.2%) |
|
| Histologic category |
|
|
|
|
<0.001 |
| epidermoide |
280 (47.0%) |
141 (36.7%) |
123 (30.8%) |
231 (30.8%) |
|
| non_epidermoide |
316 (53.0%) |
243 (63.3%) |
276 (69.2%) |
520 (69.2%) |
|
| Patients treated with immunotherapy at any line |
53 (8.9%) |
194 (50.5%) |
241 (60.4%) |
577 (76.8%) |
<0.001 |
| Patients treated with bevacizumab at any line |
75 (12.6%) |
49 (12.8%) |
53 (13.3%) |
86 (11.5%) |
0.8 |
##Courbe kaplan Meier Population globale
km_os<-survfit(Surv(cbnpc$os, cbnpc$evt_os)~1)
km_os
## Call: survfit(formula = Surv(cbnpc$os, cbnpc$evt_os) ~ 1)
##
## n events median 0.95LCL 0.95UCL
## [1,] 2130 1803 12.2 11.2 13.2
ggsurvplot(
km_os, # survfit object with calculated statistics.
data = cbnpc, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = FALSE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#2E9FDF"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##Courbe kaplan Meier selon période d'intitation de tt
km_os_periode<-survfit(Surv(os, evt_os)~initiation_period, data=cbnpc)
km_os_periode
## Call: survfit(formula = Surv(os, evt_os) ~ initiation_period, data = cbnpc)
##
## n events
## initiation_period=immunotherapy not available 596 570
## initiation_period=immunotherapy avilable as 2nd line 384 347
## initiation_period=immunotherapy available as 1st line monotherapy 399 341
## initiation_period=chemo_immunotherapy available as 1st line 751 545
## median
## initiation_period=immunotherapy not available 10.1
## initiation_period=immunotherapy avilable as 2nd line 12.1
## initiation_period=immunotherapy available as 1st line monotherapy 11.9
## initiation_period=chemo_immunotherapy available as 1st line 14.6
## 0.95LCL
## initiation_period=immunotherapy not available 9.07
## initiation_period=immunotherapy avilable as 2nd line 9.80
## initiation_period=immunotherapy available as 1st line monotherapy 10.03
## initiation_period=chemo_immunotherapy available as 1st line 13.03
## 0.95UCL
## initiation_period=immunotherapy not available 11.2
## initiation_period=immunotherapy avilable as 2nd line 14.3
## initiation_period=immunotherapy available as 1st line monotherapy 14.7
## initiation_period=chemo_immunotherapy available as 1st line 17.7
ggsurvplot(
km_os_periode, # survfit object with calculated statistics.
data = cbnpc, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = TRUE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#E7B800", "#2E9FDF", "green4", "red"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##modèle de cox os
##analyses univariée
tbl_uvregression(
cbnpc,
method = coxph,
y = Surv(os, evt_os),
exponentiate = TRUE,
include = c(old70, old65, initiation_period, young57, maigres, surpoids, obeses,bsa_cap, sexe.cat, imc, immuno, avastin, tt_initial, ir30, ir60, histologie),
pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
N |
HR |
95% CI |
p-value |
| Patients treated with immunotherapy at any line |
2,130 |
0.63 |
0.57, 0.69 |
<0.001 |
| Patients treated with bevacizumab at any line |
2,130 |
0.79 |
0.69, 0.90 |
<0.001 |
| Sex |
2,130 |
|
|
|
| F |
|
— |
— |
|
| H |
|
1.10 |
1.00, 1.22 |
0.044 |
| Body Mass Index at the start of first line |
2,130 |
0.96 |
0.95, 0.97 |
<0.001 |
| First line treatment category |
2,130 |
|
|
|
| chimio |
|
— |
— |
|
| chimio_immuno |
|
0.69 |
0.61, 0.79 |
<0.001 |
| immuno |
|
0.83 |
0.69, 1.00 |
0.048 |
| Histologic category |
2,130 |
|
|
|
| epidermoide |
|
— |
— |
|
| non_epidermoide |
|
0.87 |
0.79, 0.96 |
0.006 |
| Patients older than 70 years |
2,130 |
1.03 |
0.93, 1.15 |
0.585 |
| Patients older than 65 years |
2,130 |
1.03 |
0.94, 1.13 |
0.531 |
| Patients with BMI <18.5 |
2,130 |
1.60 |
1.40, 1.83 |
<0.001 |
| Patients with BMI >25 |
2,130 |
0.77 |
0.70, 0.85 |
<0.001 |
| Patients with BMI >30 |
2,130 |
0.76 |
0.64, 0.90 |
0.002 |
| Patients with BSA >2 |
2,130 |
0.82 |
0.72, 0.93 |
0.003 |
| Patients younger than 57 years |
2,130 |
0.94 |
0.85, 1.05 |
0.281 |
| Patients with GFR<60 ml/min |
2,103 |
1.03 |
0.88, 1.20 |
0.744 |
| Patients with GFR<30 ml/min |
2,103 |
1.79 |
1.18, 2.73 |
0.006 |
| period according to immunotherapy availability |
2,130 |
|
|
|
| immunotherapy not available |
|
— |
— |
|
| immunotherapy avilable as 2nd line |
|
0.89 |
0.78, 1.02 |
0.088 |
| immunotherapy available as 1st line monotherapy |
|
0.82 |
0.71, 0.93 |
0.003 |
| chemo_immunotherapy available as 1st line |
|
0.71 |
0.63, 0.80 |
<0.001 |
##analyses Mutlivariée
modsurv<-coxph(Surv(os, evt_os)~avastin+tt_initial+
sexe.cat+histologie+maigres+surpoids+bsa_cap+
ir30+initiation_period, data=cbnpc)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
0.79 |
0.68, 0.91 |
<0.001 |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.71 |
0.59, 0.85 |
<0.001 |
| immuno |
0.84 |
0.68, 1.02 |
0.081 |
| Sex |
|
|
|
| F |
— |
— |
|
| H |
1.17 |
1.05, 1.29 |
0.003 |
| Histologic category |
|
|
|
| epidermoide |
— |
— |
|
| non_epidermoide |
0.99 |
0.89, 1.10 |
0.863 |
| Patients with BMI <18.5 |
1.55 |
1.35, 1.79 |
<0.001 |
| Patients with BMI >25 |
0.82 |
0.73, 0.92 |
0.001 |
| Patients with BSA >2 |
0.91 |
0.78, 1.06 |
0.243 |
| Patients with GFR<30 ml/min |
1.61 |
1.05, 2.46 |
0.028 |
| period according to immunotherapy availability |
|
|
|
| immunotherapy not available |
— |
— |
|
| immunotherapy avilable as 2nd line |
0.89 |
0.78, 1.02 |
0.103 |
| immunotherapy available as 1st line monotherapy |
0.87 |
0.76, 1.01 |
0.062 |
| chemo_immunotherapy available as 1st line |
0.88 |
0.76, 1.03 |
0.108 |
##analyses Mutlivariée sans BSA plafonnée
modsurv<-coxph(Surv(os, evt_os)~avastin+tt_initial+
sexe.cat+histologie+maigres+surpoids+
ir30+initiation_period, data=cbnpc)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
0.78 |
0.68, 0.90 |
<0.001 |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.71 |
0.59, 0.85 |
<0.001 |
| immuno |
0.83 |
0.68, 1.02 |
0.073 |
| Sex |
|
|
|
| F |
— |
— |
|
| H |
1.15 |
1.04, 1.27 |
0.006 |
| Histologic category |
|
|
|
| epidermoide |
— |
— |
|
| non_epidermoide |
0.99 |
0.89, 1.10 |
0.844 |
| Patients with BMI <18.5 |
1.56 |
1.35, 1.79 |
<0.001 |
| Patients with BMI >25 |
0.80 |
0.72, 0.88 |
<0.001 |
| Patients with GFR<30 ml/min |
1.62 |
1.06, 2.47 |
0.026 |
| period according to immunotherapy availability |
|
|
|
| immunotherapy not available |
— |
— |
|
| immunotherapy avilable as 2nd line |
0.89 |
0.78, 1.02 |
0.093 |
| immunotherapy available as 1st line monotherapy |
0.88 |
0.76, 1.01 |
0.067 |
| chemo_immunotherapy available as 1st line |
0.88 |
0.76, 1.03 |
0.109 |
##analyses Multivariée sans la période
modsurv<-coxph(Surv(os, evt_os)~avastin+tt_initial+
sexe.cat+histologie+maigres+surpoids+
ir30, data=cbnpc)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
0.78 |
0.68, 0.91 |
<0.001 |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.68 |
0.59, 0.77 |
<0.001 |
| immuno |
0.79 |
0.65, 0.95 |
0.014 |
| Sex |
|
|
|
| F |
— |
— |
|
| H |
1.16 |
1.05, 1.28 |
0.004 |
| Histologic category |
|
|
|
| epidermoide |
— |
— |
|
| non_epidermoide |
0.99 |
0.89, 1.09 |
0.778 |
| Patients with BMI <18.5 |
1.56 |
1.35, 1.79 |
<0.001 |
| Patients with BMI >25 |
0.79 |
0.71, 0.88 |
<0.001 |
| Patients with GFR<30 ml/min |
1.65 |
1.08, 2.52 |
0.020 |
##analyses Mutlivariée sans l'histologie = modèle final
modsurv<-coxph(Surv(os, evt_os)~avastin+tt_initial+
sexe.cat+maigres+surpoids+
ir30, data=cbnpc)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
0.78 |
0.68, 0.90 |
<0.001 |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.67 |
0.59, 0.77 |
<0.001 |
| immuno |
0.79 |
0.65, 0.95 |
0.012 |
| Sex |
|
|
|
| F |
— |
— |
|
| H |
1.16 |
1.05, 1.28 |
0.003 |
| Patients with BMI <18.5 |
1.56 |
1.35, 1.79 |
<0.001 |
| Patients with BMI >25 |
0.79 |
0.71, 0.88 |
<0.001 |
| Patients with GFR<30 ml/min |
1.66 |
1.09, 2.53 |
0.019 |
##Analyse en sous groupes
###patients traités par immuno 1st line
immunofirst<-filter(cbnpc, c(tt_initial=="immuno" ))
####Description population immuno 1ere ligne
tbl_summary(
immunofirst, include = c("age_initiation", "old65","old70","young57","sexe.cat","poids",
"imc","maigres","surpoids","obeses","bsa_cap","dfg_ml_min","ir30" ,
"protocole_generique_initiation","histologie",
"avastin"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 164 |
| Age at the start of first line |
67 (61, 75) |
| Patients older than 65 years |
93 (56.7%) |
| Patients older than 70 years |
60 (36.6%) |
| Patients younger than 57 years |
26 (15.9%) |
| Sex |
|
| F |
57 (34.8%) |
| H |
107 (65.2%) |
| Body weight at the start of first line |
65 (55, 75) |
| Body Mass Index at the start of first line |
22.7 (20.1, 25.3) |
| Patients with BMI <18.5 |
22 (13.4%) |
| Patients with BMI >25 |
45 (27.4%) |
| Patients with BMI >30 |
8 (4.9%) |
| Patients with BSA >2 |
22 (13.4%) |
| Glomerular filtration Rate at the start of first line |
91 (71, 106) |
| Unknown |
8 |
| Patients with GFR<30 ml/min |
5 (3.2%) |
| Unknown |
8 |
| First line treatment |
|
| cemiplimab |
8 (4.9%) |
| pembrolizumab |
156 (95.1%) |
| Histologic category |
|
| epidermoide |
35 (21.3%) |
| non_epidermoide |
129 (78.7%) |
| Patients treated with bevacizumab at any line |
2 (1.2%) |
##Courbe kaplan Meier Population immuno mono 1ere ligne
km_os_immunofirst<-survfit(Surv(immunofirst$os, immunofirst$evt_os)~1)
km_os_immunofirst
## Call: survfit(formula = Surv(immunofirst$os, immunofirst$evt_os) ~
## 1)
##
## n events median 0.95LCL 0.95UCL
## [1,] 164 127 11.4 8.7 17.1
ggsurvplot(
km_os_immunofirst, # survfit object with calculated statistics.
data = immunofirst, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = FALSE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#2E9FDF"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##modèle de cox os population immuno mono 1ere ligne
##analyses univariée
tbl_uvregression(
immunofirst,
method = coxph,
y = Surv(os, evt_os),
exponentiate = TRUE,
include = c(old70, old65,young57, maigres, surpoids, obeses,bsa_cap, sexe.cat,avastin, ir30, histologie),
pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
N |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
164 |
0.37 |
0.05, 2.68 |
0.327 |
| Sex |
164 |
|
|
|
| F |
|
— |
— |
|
| H |
|
1.31 |
0.90, 1.90 |
0.156 |
| Histologic category |
164 |
|
|
|
| epidermoide |
|
— |
— |
|
| non_epidermoide |
|
0.88 |
0.58, 1.32 |
0.534 |
| Patients older than 70 years |
164 |
1.07 |
0.75, 1.54 |
0.703 |
| Patients older than 65 years |
164 |
1.10 |
0.77, 1.56 |
0.605 |
| Patients with BMI <18.5 |
164 |
1.14 |
0.69, 1.91 |
0.608 |
| Patients with BMI >25 |
164 |
0.82 |
0.55, 1.22 |
0.329 |
| Patients with BMI >30 |
164 |
0.73 |
0.32, 1.66 |
0.455 |
| Patients with BSA >2 |
164 |
0.63 |
0.37, 1.09 |
0.098 |
| Patients younger than 57 years |
164 |
1.08 |
0.67, 1.74 |
0.751 |
| Patients with GFR<30 ml/min |
156 |
3.03 |
1.23, 7.49 |
0.016 |
##patients traités par chimio-immuno 1st line
chimioimmunofirst<-filter(cbnpc, c(tt_initial=="chimio_immuno" ))
####Description population chimio immuno 1ere ligne
tbl_summary(
chimioimmunofirst, include = c("age_initiation", "old65","old70","young57","sexe.cat","poids",
"imc","maigres","surpoids","obeses","bsa_cap","dfg_ml_min","ir30",
"protocole_generique_initiation","histologie",
"avastin"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 403 |
| Age at the start of first line |
62 (56, 68) |
| Patients older than 65 years |
146 (36.2%) |
| Patients older than 70 years |
70 (17.4%) |
| Patients younger than 57 years |
116 (28.8%) |
| Sex |
|
| F |
154 (38.2%) |
| H |
249 (61.8%) |
| Body weight at the start of first line |
66 (56, 76) |
| Body Mass Index at the start of first line |
22.8 (19.9, 25.6) |
| Patients with BMI <18.5 |
57 (14.1%) |
| Patients with BMI >25 |
117 (29.0%) |
| Patients with BMI >30 |
37 (9.2%) |
| Patients with BSA >2 |
56 (13.9%) |
| Glomerular filtration Rate at the start of first line |
96 (84, 108) |
| Patients with GFR<30 ml/min |
0 (0.0%) |
| First line treatment |
|
| platine_alimta_nivolumab |
6 (1.5%) |
| platine_alimta_pembro |
335 (83.1%) |
| platine_gemcitabine_nivolumab |
1 (0.2%) |
| platine_taxol_nivolumab |
2 (0.5%) |
| platine_taxol_pembro |
59 (14.6%) |
| Histologic category |
|
| epidermoide |
62 (15.4%) |
| non_epidermoide |
341 (84.6%) |
| Patients treated with bevacizumab at any line |
60 (14.9%) |
##Courbe kaplan Meier Population chimio immuno mono 1ere ligne
km_os_chimioimmunofirst<-survfit(Surv(chimioimmunofirst$os, chimioimmunofirst$evt_os)~1)
km_os_chimioimmunofirst
## Call: survfit(formula = Surv(chimioimmunofirst$os, chimioimmunofirst$evt_os) ~
## 1)
##
## n events median 0.95LCL 0.95UCL
## [1,] 403 272 18.6 15 20.4
ggsurvplot(
km_os_chimioimmunofirst, # survfit object with calculated statistics.
data = chimioimmunofirst, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = FALSE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#2E9FDF"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##modèle de cox os population chimio immuno 1ere ligne
##analyses univariée
tbl_uvregression(
chimioimmunofirst,
method = coxph,
y = Surv(os, evt_os),
exponentiate = TRUE,
include = c(old70, old65,young57, maigres, surpoids, obeses,"bsa_cap", sexe.cat,avastin, ir30, histologie),
pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
N |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
403 |
1.00 |
0.73, 1.36 |
0.977 |
| Sex |
403 |
|
|
|
| F |
|
— |
— |
|
| H |
|
1.02 |
0.80, 1.30 |
0.874 |
| Histologic category |
403 |
|
|
|
| epidermoide |
|
— |
— |
|
| non_epidermoide |
|
0.83 |
0.59, 1.15 |
0.260 |
| Patients older than 70 years |
403 |
0.96 |
0.70, 1.32 |
0.805 |
| Patients older than 65 years |
403 |
1.02 |
0.79, 1.30 |
0.905 |
| Patients with BMI <18.5 |
403 |
1.26 |
0.90, 1.75 |
0.177 |
| Patients with BMI >25 |
403 |
0.98 |
0.75, 1.27 |
0.865 |
| Patients with BMI >30 |
403 |
1.07 |
0.71, 1.60 |
0.759 |
| Patients with BSA >2 |
403 |
0.99 |
0.70, 1.40 |
0.961 |
| Patients younger than 57 years |
403 |
1.05 |
0.81, 1.37 |
0.693 |
| Patients with GFR<30 ml/min |
403 |
|
|
|
#patients traités par chimio 1st line
chimio<-filter(cbnpc, c(tt_initial=="chimio" ))
####Description population chimio immuno 1ere ligne
tbl_summary(
chimio, include = c("age_initiation", "old65","old70","young57","sexe.cat","poids",
"imc","maigres","surpoids","obeses","bsa_cap","dfg_ml_min","ir30",
"protocole_generique_initiation","histologie",
"avastin"),
digits=all_categorical()~ c(0,1)
)
| Characteristic |
N = 1,563 |
| Age at the start of first line |
63 (57, 70) |
| Patients older than 65 years |
660 (42.2%) |
| Patients older than 70 years |
391 (25.0%) |
| Patients younger than 57 years |
415 (26.6%) |
| Sex |
|
| F |
548 (35.1%) |
| H |
1,015 (64.9%) |
| Body weight at the start of first line |
66 (56, 76) |
| Body Mass Index at the start of first line |
22.9 (20.0, 25.9) |
| Patients with BMI <18.5 |
205 (13.1%) |
| Patients with BMI >25 |
502 (32.1%) |
| Patients with BMI >30 |
128 (8.2%) |
| Patients with BSA >2 |
237 (15.2%) |
| Glomerular filtration Rate at the start of first line |
90 (75, 103) |
| Unknown |
19 |
| Patients with GFR<30 ml/min |
17 (1.1%) |
| Unknown |
19 |
| First line treatment |
|
| platine_alimta |
756 (48.4%) |
| platine_alimta_avastin |
129 (8.3%) |
| platine_docetaxel |
56 (3.6%) |
| platine_gemcitabine |
67 (4.3%) |
| platine_gemcitabine_avastin |
6 (0.4%) |
| platine_taxol |
230 (14.7%) |
| platine_taxol_avastin |
8 (0.5%) |
| platine_vinorelbine |
311 (19.9%) |
| Histologic category |
|
| epidermoide |
678 (43.4%) |
| non_epidermoide |
885 (56.6%) |
| Patients treated with bevacizumab at any line |
201 (12.9%) |
##Courbe kaplan Meier Population chimio immuno mono 1ere ligne
km_os_chimio<-survfit(Surv(chimio$os, chimio$evt_os)~1)
km_os_chimio
## Call: survfit(formula = Surv(chimio$os, chimio$evt_os) ~ 1)
##
## n events median 0.95LCL 0.95UCL
## [1,] 1563 1404 10.9 10 12.1
ggsurvplot(
km_os_chimio, # survfit object with calculated statistics.
data = chimio, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = FALSE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#2E9FDF"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##modèle de cox os population chimio 1ere ligne
##analyses univariée
tbl_uvregression(
chimio,
method = coxph,
y = Surv(os, evt_os),
exponentiate = TRUE,
include = c(old70, old65,young57, maigres, surpoids, obeses,bsa_cap, sexe.cat,avastin, ir30, histologie),
pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
N |
HR |
95% CI |
p-value |
| Patients treated with bevacizumab at any line |
1,563 |
0.74 |
0.64, 0.87 |
<0.001 |
| Sex |
1,563 |
|
|
|
| F |
|
— |
— |
|
| H |
|
1.10 |
0.98, 1.22 |
0.099 |
| Histologic category |
1,563 |
|
|
|
| epidermoide |
|
— |
— |
|
| non_epidermoide |
|
0.95 |
0.85, 1.06 |
0.343 |
| Patients older than 70 years |
1,563 |
1.01 |
0.89, 1.14 |
0.884 |
| Patients older than 65 years |
1,563 |
1.01 |
0.91, 1.13 |
0.813 |
| Patients with BMI <18.5 |
1,563 |
1.84 |
1.58, 2.14 |
<0.001 |
| Patients with BMI >25 |
1,563 |
0.72 |
0.64, 0.80 |
<0.001 |
| Patients with BMI >30 |
1,563 |
0.70 |
0.57, 0.86 |
<0.001 |
| Patients with BSA >2 |
1,563 |
0.80 |
0.69, 0.93 |
0.003 |
| Patients younger than 57 years |
1,563 |
0.91 |
0.81, 1.03 |
0.135 |
| Patients with GFR<30 ml/min |
1,544 |
1.47 |
0.91, 2.37 |
0.117 |
#Courbe de Kaplan Meier selon tt initial
##Courbe kaplan Meier selon période d'intitation de tt
km_os_tt_initial<-survfit(Surv(os, evt_os)~tt_initial, data=cbnpc)
km_os_tt_initial
## Call: survfit(formula = Surv(os, evt_os) ~ tt_initial, data = cbnpc)
##
## n events median 0.95LCL 0.95UCL
## tt_initial=chimio 1563 1404 10.9 10.0 12.1
## tt_initial=chimio_immuno 403 272 18.6 15.0 20.4
## tt_initial=immuno 164 127 11.4 8.7 17.1
ggsurvplot(
km_os_tt_initial, # survfit object with calculated statistics.
data = cbnpc, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = TRUE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#E7B800", "#2E9FDF", "green4"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
###Analyse de la période depuis AMM chimio-immuno 1ere ligne
moderne<-filter(cbnpc, c(periode==4))
##descriptif population selon traitement de 1ere ligne ere moderne
tbl_summary(
moderne, include = c("age_initiation", "old65","old70","young57","sexe.cat","poids",
"imc","maigres","obeses","bsa_cap","dfg_ml_min",
"histologie",
"imc","immuno", "avastin"),
by="tt_initial",
digits=all_categorical()~ c(0,1)
)%>%
add_p()
| Characteristic |
chimio, N = 264 |
chimio_immuno, N = 403 |
immuno, N = 84 |
p-value |
| Age at the start of first line |
68 (59, 74) |
62 (56, 68) |
68 (62, 77) |
<0.001 |
| Patients older than 65 years |
148 (56.1%) |
146 (36.2%) |
51 (60.7%) |
<0.001 |
| Patients older than 70 years |
106 (40.2%) |
70 (17.4%) |
33 (39.3%) |
<0.001 |
| Patients younger than 57 years |
49 (18.6%) |
116 (28.8%) |
12 (14.3%) |
0.001 |
| Sex |
|
|
|
0.2 |
| F |
103 (39.0%) |
154 (38.2%) |
24 (28.6%) |
|
| H |
161 (61.0%) |
249 (61.8%) |
60 (71.4%) |
|
| Body weight at the start of first line |
65 (57, 76) |
66 (56, 76) |
65 (55, 76) |
0.9 |
| Body Mass Index at the start of first line |
22.8 (20.0, 25.6) |
22.8 (19.9, 25.6) |
22.8 (20.1, 26.0) |
>0.9 |
| Patients with BMI <18.5 |
32 (12.1%) |
57 (14.1%) |
13 (15.5%) |
0.7 |
| Patients with BMI >30 |
16 (6.1%) |
37 (9.2%) |
7 (8.3%) |
0.3 |
| Patients with BSA >2 |
36 (13.6%) |
56 (13.9%) |
13 (15.5%) |
>0.9 |
| Glomerular filtration Rate at the start of first line |
90 (76, 103) |
96 (84, 108) |
86 (59, 98) |
<0.001 |
| Unknown |
0 |
0 |
6 |
|
| Histologic category |
|
|
|
<0.001 |
| epidermoide |
152 (57.6%) |
62 (15.4%) |
17 (20.2%) |
|
| non_epidermoide |
112 (42.4%) |
341 (84.6%) |
67 (79.8%) |
|
| Patients treated with immunotherapy at any line |
90 (34.1%) |
403 (100.0%) |
84 (100.0%) |
<0.001 |
| Patients treated with bevacizumab at any line |
26 (9.8%) |
60 (14.9%) |
0 (0.0%) |
<0.001 |
##Courbe kaplan Meier selon traitement initial période moderne uniquement (à partir de dec 2019)
km_os_moderne<-survfit(Surv(os, evt_os)~tt_initial, data=moderne)
km_os_moderne
## Call: survfit(formula = Surv(os, evt_os) ~ tt_initial, data = moderne)
##
## n events median 0.95LCL 0.95UCL
## tt_initial=chimio 264 211 10.4 8.27 13.8
## tt_initial=chimio_immuno 403 272 18.6 15.00 20.4
## tt_initial=immuno 84 62 13.6 9.00 26.3
ggsurvplot(
km_os_moderne, # survfit object with calculated statistics.
data = cbnpc, # data used to fit survival curves.
risk.table = TRUE, # show risk table.
pval = TRUE, # show p-value of log-rank test.
conf.int = TRUE, # show confidence intervals for
# point estimates of survival curves.
palette = c("#E7B800", "#2E9FDF", "green4"),
xlim = c(0,66), # present narrower X axis, but not affect
# survival estimates.
xlab = "Time in months", # customize X axis label.
break.time.by = 6, # break X axis in time intervals by 500.
ggtheme = theme_light(), # customize plot and risk table with a theme.
risk.table.y.text.col = T,# colour risk table text annotations.
risk.table.height = 0.25, # the height of the risk table
risk.table.y.text = FALSE,# show bars instead of names in text annotations
# in legend of risk table.
ncensor.plot = FALSE, # plot the number of censored subjects at time t
ncensor.plot.height = 0.25,
conf.int.style = "step", # customize style of confidence intervals
surv.median.line = "hv", # add the median survival pointer.
#legend.labs =
#c("no", "yes") # change legend labels.
)
##Analyse de Cox univariée sur période moderne
tbl_uvregression(
moderne,
method = coxph,
y = Surv(os, evt_os),
exponentiate = TRUE,
include = c(old70, old65, young57, maigres, surpoids, obeses,bsa_cap, sexe.cat, imc, immuno, avastin, tt_initial, ir30, ir60, histologie),
pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
N |
HR |
95% CI |
p-value |
| Patients treated with immunotherapy at any line |
751 |
0.69 |
0.57, 0.84 |
<0.001 |
| Patients treated with bevacizumab at any line |
751 |
0.88 |
0.68, 1.13 |
0.305 |
| Sex |
751 |
|
|
|
| F |
|
— |
— |
|
| H |
|
1.06 |
0.89, 1.26 |
0.514 |
| Body Mass Index at the start of first line |
751 |
0.97 |
0.95, 0.99 |
0.002 |
| First line treatment category |
751 |
|
|
|
| chimio |
|
— |
— |
|
| chimio_immuno |
|
0.72 |
0.60, 0.87 |
<0.001 |
| immuno |
|
0.80 |
0.60, 1.06 |
0.124 |
| Histologic category |
751 |
|
|
|
| epidermoide |
|
— |
— |
|
| non_epidermoide |
|
0.76 |
0.63, 0.91 |
0.002 |
| Patients older than 70 years |
751 |
1.15 |
0.95, 1.38 |
0.145 |
| Patients older than 65 years |
751 |
1.20 |
1.01, 1.42 |
0.034 |
| Patients with BMI <18.5 |
751 |
1.60 |
1.26, 2.03 |
<0.001 |
| Patients with BMI >25 |
751 |
0.80 |
0.66, 0.96 |
0.017 |
| Patients with BMI >30 |
751 |
0.85 |
0.62, 1.17 |
0.326 |
| Patients with BSA >2 |
751 |
0.82 |
0.64, 1.05 |
0.124 |
| Patients younger than 57 years |
751 |
0.84 |
0.69, 1.03 |
0.093 |
| Patients with GFR<60 ml/min |
745 |
1.46 |
1.09, 1.96 |
0.011 |
| Patients with GFR<30 ml/min |
745 |
2.61 |
1.35, 5.05 |
0.004 |
##analyses Mutlivariée sur période moderne
modsurv<-coxph(Surv(os, evt_os)~tt_initial+
histologie+maigres+surpoids+young57+
ir30, data=moderne)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.75 |
0.61, 0.92 |
0.005 |
| immuno |
0.83 |
0.62, 1.12 |
0.234 |
| Histologic category |
|
|
|
| epidermoide |
— |
— |
|
| non_epidermoide |
0.86 |
0.70, 1.05 |
0.139 |
| Patients with BMI <18.5 |
1.66 |
1.30, 2.13 |
<0.001 |
| Patients with BMI >25 |
0.82 |
0.67, 1.00 |
0.047 |
| Patients younger than 57 years |
0.82 |
0.66, 1.00 |
0.054 |
| Patients with GFR<30 ml/min |
2.29 |
1.18, 4.47 |
0.015 |
##analyses Mutlivariée sans histologie
modsurv<-coxph(Surv(os, evt_os)~tt_initial+
maigres+surpoids+young57+
ir30, data=moderne)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.70 |
0.59, 0.84 |
<0.001 |
| immuno |
0.79 |
0.59, 1.06 |
0.118 |
| Patients with BMI <18.5 |
1.65 |
1.29, 2.12 |
<0.001 |
| Patients with BMI >25 |
0.82 |
0.67, 1.0 |
0.044 |
| Patients younger than 57 years |
0.81 |
0.66, 0.99 |
0.042 |
| Patients with GFR<30 ml/min |
2.38 |
1.22, 4.64 |
0.011 |
##analyses Mutlivariée sans histologie avec dfg<60 à la place de dfg<30
modsurv<-coxph(Surv(os, evt_os)~tt_initial+
maigres+surpoids+young57+
ir60, data=moderne)
modsurv%>%tbl_regression(
exponentiate = TRUE,pvalue_fun = scales::label_pvalue(accuracy = .001)
)
| Characteristic |
HR |
95% CI |
p-value |
| First line treatment category |
|
|
|
| chimio |
— |
— |
|
| chimio_immuno |
0.71 |
0.59, 0.86 |
<0.001 |
| immuno |
0.77 |
0.58, 1.04 |
0.087 |
| Patients with BMI <18.5 |
1.65 |
1.29, 2.12 |
<0.001 |
| Patients with BMI >25 |
0.82 |
0.68, 1.00 |
0.053 |
| Patients younger than 57 years |
0.82 |
0.66, 1.01 |
0.057 |
| Patients with GFR<60 ml/min |
1.31 |
0.96, 1.79 |
0.083 |